Washington Post Publisher Will Lewis Steps Down After Layoffs 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
NEW YORK, March 05, 2018 -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced that Angelos Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS, will present a corporate overview at the 30th Annual ROTH Conference on Monday, March 12, 2018 at 9:00 a.m. PT in Orange County, CA.
A live audio webcast of the presentation will be available under “Events & Presentations” in the Investors section of SELLAS’ website at www.sellaslifesciences.com/investors. A replay of the webcast will be available for up to 30 days on SELLAS’ website following the presentation.
About SELLAS Life Sciences Group
SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS has Phase 3 clinical trials planned (pending funding availability) for GPS in two indications, acute myeloid leukemia (AML) and malignant pleural mesotheliomia (MPM) and is also developing GPS as a potential treatment for multiple myeloma and ovarian cancer. SELLAS plans to study GPS in up to four additional indications. SELLAS has received Orphan Drug designations from the U.S. Food & Drug Administration (FDA), as well as the European Medicines Agency, for GPS in AML and MPM; GPS also received Fast Track designation for AML and MPM from the FDA.
For more information on SELLAS, please visit www.sellaslifesciences.com.
Investor Contact:
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
[email protected]
David Moser, JD
SELLAS Life Sciences Group, Inc.
813-864-2571
[email protected]
Source: SELLAS Life Sciences Group, Inc.
